Arca
Skip to content
Tools
Tools

CALCA, CALCB: Calcitonin gene-related peptide

Family in Homo sapiens that 3 drugs act on.

  • Drugs that act on it: 3
  • Approved: 3
  • In phases 1 to 3: 0
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on CALCA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 3

Approved3

  • Eptinezumab
  • Fremanezumab
  • Galcanezumab

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        EptinezumabApprovedLundbeckAntibodyInhibitorCalcitonin gene-related peptide inhibitor16
        FremanezumabApprovedTeva Pharmaceutical IndustriesAntibodyAntagonistCalcitonin gene-related peptide antagonist11
        GalcanezumabApprovedEli LillyAntibodyInhibitorCalcitonin gene-related peptide inhibitor10

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 17 in all, from ClinicalTrials.gov.
        Migraine Menopause StudyEptinezumabPhase 4Not yet recruitingAlberta Neurologic CentreNov 4, 2026
        Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)FremanezumabPhase 1Not yet recruitingM.D. Anderson Cancer CenterSep 21, 2026
        Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Eptinezumab, Fremanezumab, GalcanezumabPhase 4Not yet recruitingStanford UniversityJun 17, 2026
        Calcitonin Gene-related Peptide Antibody in Acute Mountain SicknessFremanezumabPhase 4Not yet recruitingInsel Gruppe AG, University Hospital BernJun 17, 2026
        Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionEptinezumabPhase 3Not yet recruitingRigmor Højland JensenJun 12, 2026
        Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's DiseaseGalcanezumabEarly phase 1RecruitingXuanwu Hospital, BeijingJan 7, 2026
        Treatment of Atypical Resistant Facial PainEptinezumab—Enrolling by invitationAlenka Spindler-VeselNov 26, 2025
        Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)EptinezumabPhase 3RecruitingSunnybrook Health Sciences CentreSep 24, 2025
        Real-world Prospective Study on the Use of Anti-CGRP Drugs in MigraineEptinezumab, Fremanezumab, Galcanezumab—RecruitingHospital Universitari Vall d'Hebron Research InstituteSep 8, 2025
        i-NEED: NEw migrainE Drugs DatabaseEptinezumab, Fremanezumab, Galcanezumab—RecruitingIRCCS San Raffaele RomaAug 5, 2025
        New Methods for Evaluating Preventive Migraine TreatmentFremanezumabNot applicableRecruitingUniversity of AarhusJul 17, 2025
        Fremanezumab for the Prevention of Menstrually-related Migraine AttacksFremanezumab—RecruitingInsel Gruppe AG, University Hospital BernOct 26, 2024
        The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)Eptinezumab—RecruitingUniversity of FlorenceOct 8, 2024
        Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP AntibodiesFremanezumab, Galcanezumab—Active, not recruitingFundación de Investigación Biomédica - Hospital Universitario de La PrincesaJun 14, 2024
        Migraine Medication Effects on Urinary SymptomsGalcanezumab—Enrolling by invitationThe Cleveland ClinicJan 19, 2024
        Emgality for Migraine in BreastmilkGalcanezumab—RecruitingUniversity of California, San FranciscoOct 16, 2023
        CGRP Inhibition, Autonomic Function, and MigraineGalcanezumab—RecruitingMedical University of ViennaNov 13, 2020

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3832947, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.